Evidence mapPaperPMID 35454947Full record

ArticleCancers2022

Multi-Omics Approach Points to the Importance of Oxylipins Metabolism in Early-Stage Breast Cancer.

Dmitry V Chistyakov, Mariia V Guryleva, Elena S Stepanova, Lyubov M Makarenkova, Elena V Ptitsyna, Sergei V Goriainov, Arina I Nikolskaya, Alina A Astakhova, Anna S Klimenko, Olga A Bezborodova and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Identification of a Novel Biomarker Panel for Breast Cancer Screening.International journal of molecular sciences · 2024
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Dmitry V ChistyakovBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
Mariia V GurylevaFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia.
Elena S StepanovaPeoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
Lyubov M MakarenkovaPeoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
Elena V PtitsynaFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia.
Sergei V GoriainovPeoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
Arina I NikolskayaFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia.
Alina A AstakhovaBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
Anna S KlimenkoPeoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
Olga A BezborodovaNational Medical Radiology Research Center, P. Hertsen Research Institute of Oncology, 125284 Moscow, Russia.ORCID 0000-0002-5009-1508
Elena A RasskazovaNational Medical Radiology Research Center, P. Hertsen Research Institute of Oncology, 125284 Moscow, Russia.
Olga G PotaninaFaculty of Medicine, Lomonosov Moscow State University, 119991 Moscow, Russia.
Rimma A AbramovichFaculty of Medicine, Lomonosov Moscow State University, 119991 Moscow, Russia.
Elena R NemtsovaNational Medical Radiology Research Center, P. Hertsen Research Institute of Oncology, 125284 Moscow, Russia.
Marina G SergeevaBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
Lomonosov Moscow State University · RUPeoples' Friendship University of Russia · RUP.A. Hertzen Moscow Oncology Research Institute · RU

Funding

Russian Foundation for Basic Research 19-29-01243
6 · The paper itself

Abstract

The involvement of oxylipins, metabolites of polyunsaturated fatty acids, in cancer pathogenesis was known long ago, but only the development of the high-throughput methods get the opportunity to study oxylipins on a system level. The study aimed to elucidate alterations in oxylipin metabolism as characteristics of breast cancer patients. We compared the ultra-high-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) oxylipin profile signatures in the blood plasma of 152 healthy volunteers (HC) and 169 patients with different stages of breast cancer (BC). To integrate lipidomics, transcriptomics, and genomics data, we analyzed a transcriptome of 10 open database datasets obtained from tissues and blood cells of BC patients and SNP data for 33 genes related to oxylipin metabolism. We identified 18 oxylipins, metabolites of omega-3 or omega-6 polyunsaturated fatty acids, that were differentially expressed between BCvsHC patients, including anandamide, prostaglandins and hydroxydocosahexaenoic acids. DEGs analysis of tissue and blood samples from BC patients revealed that 19 genes for oxylipin biosynthesis change their expression level, with CYP2C19, PTGS2, HPGD, and FAAH included in the list of DEGs in the analysis of transcriptomes and the list of SNPs associated with BC. Results allow us to suppose that oxylipin signatures reflect the organism's level of response to the disease. Our data regarding changes in oxylipins at the system level show that oxylipin profiles can be used to evaluate the early stages of breast cancer.

Indexed as

anandamidebreast cancerCOXCYP450lipidomicsLOXoxylipinsPUFAstranscriptomicsUPLC-MS/MS

Identifiers

PMID35454947
PMCPMC9032865
OpenAlexW4224257488

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.